Literature DB >> 18983484

Cardiovascular disease in patients with hemophilia.

A Tuinenburg1, E P Mauser-Bunschoten, M C Verhaar, D H Biesma, R E G Schutgens.   

Abstract

Mortality due to ischemic heart disease in hemophilia patients is lower as compared to the general male population. Differences in the prevalence of cardiovascular risk factors cannot explain this finding. The hypocoagulable state of hemophilia patients might have a protective effect on thrombus formation, which precipitates infarction. It remains unclear whether the deficiency of coagulation factor VIII or IX exerts a protective effect on the development of atherosclerosis. Despite the relative protection against cardiovascular events, the incidence of ischemic cardiovascular disease in hemophilia patients is increasing, because life expectancy of these patients now approaches that of the general population. This review focuses on what is currently known about cardiovascular risk factors, atherosclerosis, arterial thrombosis and ischemic cardiovascular disease in hemophilia patients.

Entities:  

Mesh:

Year:  2008        PMID: 18983484     DOI: 10.1111/j.1538-7836.2008.03201.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  19 in total

Review 1.  Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Authors:  Thomas J Povsic; Bruce A Sullenger; Steven L Zelenkofske; Christopher P Rusconi; Richard C Becker
Journal:  J Cardiovasc Transl Res       Date:  2010-11-16       Impact factor: 4.132

Review 2.  Can haemostatic factors predict atherothrombosis?

Authors:  Gordon Lowe
Journal:  Intern Emerg Med       Date:  2011-02-15       Impact factor: 3.397

3.  Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A.

Authors:  M V Ragni; C G Moore
Journal:  Haemophilia       Date:  2011-03-04       Impact factor: 4.287

Review 4.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

5.  Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture.

Authors:  Zhi Xu; Francis J Castellino; Victoria A Ploplis
Journal:  Blood       Date:  2009-12-15       Impact factor: 22.113

6.  Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project.

Authors:  Elena Santagostino; Maria Messina; Annarita Tagliaferri; Alfonso Iorio; Massimo Morfini
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

Review 7.  Management of Hemophilia in Older Patients.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

8.  Countervailing effects on atherogenesis and plaque stability: a paradoxical benefit of hypercoagulability?

Authors:  Jeff W Stevens; Steven R Lentz
Journal:  Circulation       Date:  2009-08-17       Impact factor: 29.690

Review 9.  Translation and Clinical Development of Antithrombotic Aptamers.

Authors:  Shahid M Nimjee; Thomas J Povsic; Bruce A Sullenger; Richard C Becker
Journal:  Nucleic Acid Ther       Date:  2016-02-16       Impact factor: 5.486

10.  Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice.

Authors:  Kellie R Machlus; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.